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OBJECTIVE—To determine whether circulating levels of the
inﬂammatory markers C-reactive protein (CRP), interleukin
(IL)-6, and tumor necrosis factor (TNF)- are associated with
cognitive ability and estimated lifetime cognitive decline in an
elderly population with type 2 diabetes.
RESEARCH DESIGN AND METHODS—A cross-sectional
study of 1,066 men and women aged 60–75 years with type 2
diabetes and living in Lothian, Scotland (the Edinburgh Type 2
Diabetes Study), was performed. Seven cognitive tests were used
to measure abilities in memory, nonverbal reasoning, informa-
tion processing speed, executive function, and mental ﬂexibility.
The results were used to derive a general intelligence factor (g).
A vocabulary–based test was administered as an estimate of
peak prior cognitive ability. Results on the cognitive tests were
assessed for statistical association with inﬂammatory markers
measured in a venous blood sample at the time of cognitive
testing.
RESULTS—Higher IL-6 and TNF- levels were associated with
poorer age- and sex-adjusted scores on the majority of the
individual cognitive tests. They were also associated with g using
standardized regression coefﬁcients 0.074 to 0.173 (P  0.05).
After adjusting for vocabulary, education level, cardiovascular
dysfunction, duration of diabetes, and glycemic control, IL-6
remained associated with three of the cognitive tests and with g.
CONCLUSIONS—In this representative population of people
with type 2 diabetes, elevated circulating levels of inﬂammatory
markers were associated with poorer cognitive ability. IL-6 levels
were also associated with estimated lifetime cognitive decline.
Diabetes 59:710–713, 2010
T
ype 2 diabetes is associated with an increased
risk of cognitive impairment in older age, accel-
erated age-related cognitive decline, and a higher
incidence of dementia (1). Identifying potentially
modiﬁable risk factors for cognitive impairment in people
with type 2 diabetes is therefore of major importance for
future diabetes health care initiatives and the reduction of
cognitive morbidity in the general population.
The cause of cognitive impairment in type 2 diabetes is
unknown, but it is most likely multifactorial. Hyperglyce-
mia, cerebral microvascular disease, severe hypoglycemia,
and an increased prevalence of macrovascular disease
have all been implicated but are unlikely to explain the
entire effect (2). Systemic or cerebral inﬂammation may
also be important, and evidence of chronic inﬂammation
has been observed in the brains of people with dementia
(3). Levels of circulating inﬂammatory markers are ele-
vated in people with type 2 diabetes compared with an
equivalent nondiabetic population (4). Inﬂammatory me-
diators may therefore have a role in the accelerated
development of cognitive impairment in people with dia-
betes either by a direct effect on the brain or through an
inﬂuence on the development of vascular disease.
The Edinburgh Type 2 Diabetes Study (ET2DS) tested
the association between three markers of inﬂammation
(C-reactive protein [CRP], interleukin [IL]-6, and tumor
necrosis factor [TNF]-) and cognitive impairment in a
representative cohort of people with type 2 diabetes.
RESEARCH DESIGN AND METHODS
The ET2DS is a sample of men and women aged 60–75 years with type 2
diabetes. The subjects were randomly selected by sex and 5-year age bands
from the comprehensive Lothian Diabetes Register (LDR) of people with type
2 diabetes living in Lothian, Scotland. A sample size of 1,000 was targeted to
detect associations between baseline risk factors and both cognitive ability at
baseline and cognitive change during subsequent follow-up. Exclusion crite-
ria, applied at the time of physical examination, have been reported previously
(5). All subjects provided written informed consent, and the study was
approved by the Lothian Research Ethics Committee.
Clinical assessment. Physical examinations were performed between Au-
gust 2006 and August 2007 by trained researchers using standard operating
procedures (5). Quality control measures included tests of inter- and intra-
observer variability. A fasting venous blood sample was taken for measure-
ment of inﬂammatory markers, total serum cholesterol, and plasma A1C.
Following measurements of height and weight, a 12-lead electrocardiogram
(ECG) was taken for subsequent Minnesota coding (http://www.epi.umn.edu/
ecg/). After a 10-min rest in the supine position, systolic and diastolic blood
pressure was measured in the right arm using a standard stethoscope and
aneroid dial sphygmomanometer. Right and left brachial, posterior tibial, and
dorsalis pedis systolic pressures were then taken using an aneroid sphygmo-
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questions on education; history of myocardial infarction (MI), stroke or
angina; year of diabetes diagnosis; smoking; current medications; and the
World Health Organization (WHO) chest pain questionnaire (6). Data were
collected from the Information and Services Division of the National Health
Service (NHS) Health Services Scotland on all medical and surgical discharges
from Scottish hospitals since 1981 (Scottish Morbidity Record [SMR01]
scheme [7]), and any ICD-10 codes (or the equivalent ICD-9 codes) indicating
cardiovascular or cerebrovascular disease were extracted.
Cognitive assessment. Cognitive assessment took place after a snack and
conﬁrmation that blood glucose was 4 mmol/l. Fluid cognitive ability was
assessed using tests of: nonverbal memory and immediate and delayed verbal
declarative memory (Faces and Family Pictures Subtest, Logical Memory
subtest from the Wechsler Memory Scale III
U.K. [8]); working memory,
nonverbal reasoning, and processing speed (Letter Number Sequencing,
Matrix Reasoning, Digit Symbol Test from the Wechsler Adult Intelligence
Scale-III [WAIS III
U.K.] [9]); executive function (Verbal Fluency Test[10]); and
mental ﬂexibility (Trail Making Test–Part B [11]). Vocabulary (crystallized
intelligence) was measured using the combined Junior and Senior Mill Hill
Vocabulary Scale (MHVS) synonyms (12). As results on vocabulary-based
tests vary little with ageing, they can be used to approximate peak prior
cognitive ability (13). Late-life cognition adjusted for vocabulary also corre-
lates highly with actual cognitive change (14). The Hospital Anxiety and
Depression Scale (15) was also administered because mood can affect
cognitive test results.
Measurement of inﬂammatory markers. Blood samples were processed at
the research clinic, and plasma was stored at 40°C. Assays for plasma CRP,
IL-6, and TNF- were performed in the University Department of Medicine,
Glasgow Royal Inﬁrmary. CRP was assayed using a high-sensitivity immunon-
ephelometric assay (16). TNF- and IL-6 antigen levels were determined using
high-sensitivity ELISA kits (R&D Systems, Oxon, U.K.).
Data analysis. Information on the questionnaire and recording forms was
checked by clinic staff. Two clerks independently entered the data onto an
Access database. Errors identiﬁed by comparing the double data entries were
resolved by referring to the paper records. Anonymized data on demographic
and clinical variables from the LDR were used to compare the characteristics
of study responders and nonresponders.
Ankle brachial index, a measure of subclinical atherosclerosis (17), was
calculated by dividing the lowest of the ankle pressures by the higher of the
arm pressures. Smoking was categorized as current, ex, or never-smoked,
with anyone stopping within the past 6 months recategorized as a current
smoker. Duration of diabetes was calculated to the nearest year by subtracting
the self-reported year of diagnosis from the date of attendance at the research
clinic. The highest self-reported level of education was categorized as primary,
secondary, professional qualiﬁcation, or university/college degree. Scottish
Index of Multiple Deprivation (deprivation) (18) was assigned to each subject
according to their postcode of residence. The following criteria were used to
deﬁne MI: 1) subject recall of a doctor’s diagnosis of MI, 2) positive WHO
chest pain questionnaire for MI, 3) ECG evidence of ischemia (Minnesota
codes 1.1–1.3, 4.1–4.2, 5.1–5.3 or 7.1), and 4) prior hospital discharge code for
MI (ICD-10 codes I21–I23, I252). MI was recorded if two of the ﬁrst three
criteria were met or if both the ﬁrst and last criteria were met. Equivalent
criteria for angina were: 1) subject recall of a doctor’s diagnosis of the
condition or being on regular medication for angina, 2) positive WHO chest
pain questionnaire for angina, 3) ECG evidence of ischemia, and 4) prior
hospital discharge code for ischemic heart disease (ICD-10 codes I20–I25).
Angina was recorded if two of the ﬁrst three criteria were met or if both the
ﬁrst and last criteria were met. Stroke was recorded if two of three of the
following criteria were met: 1) subject recall of a doctor’s diagnosis of stroke,
2) prior hospital discharge code consistent with stroke (ICD-10 codes I61,
I63–I66, I679, I694), and 3) conﬁrmation by review of clinical notes that the
event was not due to a transient ischemic attack.
Continuous variables were normally distributed apart from Trail Making
Test scores, CRP, IL-6, and TNF- levels, which were transformed using
natural logarithms. The inﬂammatory markers were trimmed for points
exceeding 3.5 SDs from the mean prior to analysis. Scores from the ﬂuid
cognitive tests were used to obtain a general cognitive ability factor (g) via
principal components analysis.
Age- and sex-adjusted linear regression assessed the association between
cognitive scores and inﬂammatory markers. Further adjustments were made
for vocabulary (MHVS) and then for additional covariates to adjust for mood
(Hospital Anxiety and Depression Scale depression score), duration of
diabetes, glycemic control (plasma A1C), cardiovascular risk factors (total
cholesterol, BMI, diastolic blood pressure, smoking), cardiovascular disease
(MI, angina, stroke, ankle brachial index), and level of education. The analyses
had over 90% power for a two-sided signiﬁcance test (0.05) to detect a
standardized  coefﬁcient of 0.10. Analyses were performed using R version
2.7.0 (19).
RESULTS
From 5,454 invitations sent out, 1,252 people initially
agreed to participate in the study and 1,066 (85%) were
recruited. Crude response rates varied between sex and
5-year age bands, from 13.6% in the oldest women aged
70–74 years, to 27.5% in men aged 65–69 years. Study
participants were found to be similar to the 4,388 nonre-
sponders (Table 1). Despite some statistically signiﬁcant
differences in demographic and clinical characteristics,
the actual differences were small and of questionable
clinical signiﬁcance. Similarities persisted when compari-
son was made by sex and 5-year age band and when
adjustment was made for error rates in LDR data record-
ing (data not shown). A summary of the study participants
is presented in Table 2.
Age- and sex-adjusted associations between inﬂamma-
tory marker levels and cognitive test scores are shown in
Table 3. Associations for CRP were weakly signiﬁcant or
nonsigniﬁcant. The associations for IL-6 and TNF- were
larger and statistically signiﬁcant for the majority of the
tests with standardized coefﬁcients ranging from 0.074 to
0.173 (all P  0.05).
All inﬂammatory measures associated with age- and
sex-adjusted MHVS scores with standardized coefﬁcients
were: CRP 0.075 (P  0.05), IL-6 0.091 (P  0.01), and
TNF- 0.087 (P  0.05).
Age, sex, and vocabulary adjustment weakened the
magnitude and statistical signiﬁcance of the associations
(Table 3). However, the strongest IL-6 and TNF- associ-
ations were retained after adjustments for both vocabulary
and the other covariates. This was particularly evident for
IL-6 with standardized coefﬁcients for the full models in
the ranges 0.074 to 0.113.
TABLE 1
Characteristics and clinical features of the ET2DS population
and nonresponders
ET2DS
population Nonresponders
n 1,066 4,386*
Age (years) 67.9  4.20 67.9  4.35
Male sex 547 (51.3) 1,839 (41.9)§
Duration of diabetes
Up to 5 years 516 (48.4) 2,135 (48.7)
5 years 550 (51.6) 2,251 (51.3)
A1C (%) 7.4 (1.12) 7.4 (1.36)
Insulin treatment 185 (17.4) 704 (16.1)
Systolic BP (mmHg) 133.3  16.44 137.2  18.15§
Total cholesterol (mmol/l) 4.3 (0.90) 4.2 (0.96)‡
Quintile for SIMD
Missing 0  01 6  0.4§
1 127  11.9 736  16.8
2 208  19.5 1,134  25.9
3 188  17.6 820  18.7
4 194  18.2 782  17.8
5 349  32.7 897  20.5
Data are means  SD or n (%). *Two subjects on the LDR had no data
and were discarded from the analyses (i.e., total number of nonre-
sponders was 4,388); ‡P  0.01; §P  0.001 (
2 test for independence
or t test for differences between groups). BP, blood pressure; SIMD,
Scottish Index of Multiple Deprivation.
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In this representative population of people with type 2
diabetes, elevated levels of plasma CRP, IL-6, and TNF-
were signiﬁcantly associated with poorer age- and sex-
adjusted general cognitive abilities. The maximum effect
size for the age- and sex-adjusted g associations was with
IL-6, which corresponded to a 0.173 decrease in g for every
twofold increase in IL-6 levels.
Adjustments for cardiovascular disease/risk factors, gly-
cemic control, duration of diabetes, and education re-
sulted in reductions to the effect sizes. However, this does
not indicate whether these factors are confounders or
whether they could be mediators in the same pathway
leading to cognitive decline. The association between IL-6
and g, although weakened, remained statistically signiﬁ-
cant after full multivariate adjustment, suggesting a possi-
ble role for IL-6 in cognitive decline. Analyses were
repeated to exclude potential dementia cases (Mini Mental
State Examination score 24, n  33), but this did not
affect the results.
TABLE 2
Characteristics and clinical features of the ET2DS population
n 1,066
Age (years) 67.9  4.20
Male sex 547 (51.3)
Duration of diabetes (years) 8.1  6.46
Duration of diabetes
Up to 5 years 516 (48.4)
5 years 550 (51.6)
A1C (%) 7.4  1.12
Insulin treatment 185 (17.4)
Systolic BP (mmHg) 133.3  16.44
Diastolic BP (mmHg) 69.1  9.02
Total cholesterol (mmol/l) 4.3  0.90
BMI (kg/m
2) 31.4  5.69
Smoker
Current 153 (14.4)
Ex-smoker 499 (46.8)
Never smoked 414 (38.8)
CHD (yes) 330 (31.0)
Stroke (yes) 62 (5.8)
Ankle-brachial index 0.98  0.21
Education*
Primary school 7 (0.7)
Secondary school 581 (54.5)
Professional qualiﬁcation 307 (28.8)
University/college 171 (16.0)
HADS depression score 3 (1–6)
CRP (mg/l) 1.86 (0.87–4.37)
IL-6 (pg/ml) 2.87 (1.97–4.46)
TNF- (pg/ml) 1.07 (0.69–1.62)
MR 12.8  5.28
LNS 9.7  2.75
VFT 36.9  12.83
DST 49.2  14.77
TMT 104 (81–138)
FACES 65.8  7.88
LM 25.2  8.17
g 0.00  1.00
MHVS 30.9  5.23
Data are means  SD, median (quartile range), or n (%). *Self-
reported highest education level attained. BP, blood pressure; CHD,
coronary heart disease (MI or angina); DST, digit symbol test;
FACES, Faces and Family Pictures Subtest; HADS, Hospital Anxiety
and Depression Scale; LM, logical memory; LNS, letter-number
sequencing; MR, matrix reasoning; TMT, Trail Making Test-Part B;
VFT, Verbal Fluency Test.
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gated the relationship between inﬂammatory biomarkers
and cognition in nondiabetic populations. These studies
have found associations of a modest but similar order to
those reported in the present study (20–24). As all our
study participants had diabetes, we were not able to
formally test for a differential effect size in diabetes.
The strengths of the present study include the applica-
tion of a cognitive test battery covering major cognitive
domains and extensive phenotyping for potential con-
founding or mediating factors. The use of a general
cognitive factor (g) helped avoid potential problems
caused by multiple testing. The study population had a
veriﬁed clinical diagnosis of type 2 diabetes and was
shown to be representative of the target population of
elderly, community-dwelling men and women with the full
spectrum of severity of type 2 diabetes (from diet-con-
trolled to insulin-treated).
Although cross-sectional, the present results provide the
best epidemiological evidence to date for an inﬂammation-
cognition relationship in people with type 2 diabetes. As
markers of inﬂammation are sensitive to acute illness and
alter with age, it is questionable whether a single, late-life
measurement accurately reﬂects the lifetime risk of expo-
sure to inﬂammation (25). This will be addressed in
follow-up phases of the ET2DS, when inﬂammatory mark-
ers and cognition will be remeasured and genetic predic-
tors of inﬂammatory markers will be studied.
In conclusion, raised circulating inﬂammatory marker
levels are associated with poorer late-life cognitive ability
in people with type 2 diabetes, even after adjustment for a
vocabulary-based estimate of peak prior cognitive ability.
These ﬁndings were particularly notable for IL-6. Future
longitudinal studies are required to conﬁrm the direction
of the association and whether there is evidence for
causality.
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